Evaluate the safety of AZD8683 by assessing the frequency of adverse events [ Time Frame: Adverse events are captured from screening and captured on each clinic day and on the follow up day. ] [ Designated as safety issue: Yes ]

Evaluate the safety of AZD8683 by assessing a panel of laboratory safety assessments [ Time Frame: Lab safety assessments are taken at screening, pre-dose on day 1 and then 24 hours, and 48 hours post-dose and again on follow up. ] [ Designated as safety issue: Yes ]

Evaluate the safety of AZD8683 by assessing physical examination [ Time Frame: A physical examination is conducted at screening, day -1, day 3 and again at follow-up. ] [ Designated as safety issue: Yes ]

To investigate the pharmacodynamics (PD) of inhaled single ascending doses of AZD8683 in healthy subjects including the Forced Expiratory Volume in 1 second (FEV1) [ Time Frame: Spirometry for FEV1 is conducted pre-dose and at 5 minutes, 15 minutes, 1 hour, 2 hours and 4 hourspost dose. ] [ Designated as safety issue: No ]

Provision of signed and dated, written informed consent prior to any study specific procedures Healthy male subjects aged 18

45 years with suitable veins for cannulation or repeated venepuncture

Male subjects should be willing to use barrier contraception ie, condoms and spermicide, from the day of dosing until at least 3 months after dosing with the investigational product

Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive

Exclusion Criteria:

History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs

Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product

Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

Systolic blood pressure >140 mm Hg

Diastolic blood pressure >90 mm Hg

Heart rate <40 or >85 beats per minute Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG. This includes subjects with any of the following:

PR(PQ) interval prolongation >200 ms or dropped beats (single non conducted P-waves) based on screening or Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01419600